PIK3CA Mutations and Their Response to Neoadjuvant Treatment in Early Breast Cancer: A Systematic Review and Meta-Analysis
作者： Hongwei Fan , Chao Li , Qian Xiang , Ling Xu , Zhuo Zhang
关键词: Oncology 、 Pathological 、 Relative risk 、 Meta-analysis 、 Neoadjuvant treatment 、 Wild type 、 Confidence interval 、 Breast cancer 、 Exon 、 Medicine 、 Internal medicine
摘要: Background PIK3CA mutations frequently occur in breast cancer patients. This study was conducted to evaluate the relationship between and neoadjuvant treatment response analyze clinical implications. Methods PubMed, Embase, Cochrane database were searched for relevant studies September 2017. The pooled risk ratio (RR) estimated using fixed effects or random models according heterogeneity among studies. Results meta-analysis included 20 with 4392 RR showed that mutation is correlated lower pathological complete (pCR) unselected HER2+ patients (RR = 0.73; 95% confidence interval [CI] 0.66-0.81), thus predictive value of status may be stronger HER2+/HR+ 0.50; CI 0.27-0.93) those administered dual-targeting 0.55; 0.39-0.78). In contrast wild type, either exon 9 0.39-0.78) 0.71; 0.58-0.89) significantly associated pCR. not greater than 0.76; 0.51-1.13). Conclusion early cancer, seem identify who are less likely reach implications tend vary 20. mechanism should explored further
sci-hub.se 参考文章(37)
Jonas Cicenas, Patrick Urban, Vincent Vuaroqueaux, Martin Labuhn, Willy Küng, Edward Wight, Mark Mayhew, Urs Eppenberger, Serenella Eppenberger-Castori, Increased level of phosphorylated akt measured by chemiluminescence-linked immunosorbent assay is a predictor of poor prognosis in primary breast cancer overexpressing ErbB-2 Breast Cancer Research. ,vol. 7, pp. 1- 8 ,(2005) , 10.1186/BCR1015
Liang Huang, Sheng Chen, Wentao Yang, Binghe Xu, Tao Huang, Hongjian Yang, Hong Zheng, Yongsheng Wang, Erwei Song, Jin Zhang, Shude Cui, Da Pang, Lili Tang, Yutao Lei, Cuizhi Geng, Zhiming Shao, Efficacy and safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy for clinical stage II-III, HER2-positive breast cancer patients: a phase 2, open-label, multicenter, randomized trial Oncotarget. ,vol. 6, pp. 18683- 18692 ,(2015) , 10.18632/ONCOTARGET.4337
Esther H. Lips, , Magali Michaut, Marlous Hoogstraat, Lennart Mulder, Nicolle JM Besselink, Marco J. Koudijs, Edwin Cuppen, Emile E. Voest, Rene Bernards, Petra M. Nederlof, Jelle Wesseling, Sjoerd Rodenhuis, Lodewyk FA Wessels, Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response. Breast Cancer Research. ,vol. 17, pp. 134- 134 ,(2015) , 10.1186/S13058-015-0642-8
B Karakas, K E Bachman, B H Park, Mutation of the PIK3CA oncogene in human cancers. British Journal of Cancer. ,vol. 94, pp. 455- 459 ,(2006) , 10.1038/SJ.BJC.6602970
Aiko Sueta, Yutaka Yamamoto, Mutsuko Yamamoto-Ibusuki, Mitsuhiro Hayashi, Takashi Takeshita, Satoko Yamamoto, Hirotaka Iwase, An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer PLOS ONE. ,vol. 9, ,(2014) , 10.1371/JOURNAL.PONE.0116054
Matthew J. Ellis, Li Lin, Robert Crowder, Yu Tao, Jeremy Hoog, Jacqueline Snider, Sherri Davies, Katherine DeSchryver, Dean B. Evans, Jutta Steinseifer, Raj Bandaru, WeiHua Liu, Humphrey Gardner, Vladimir Semiglazov, Mark Watson, Kelly Hunt, John Olson, José Baselga, Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Research and Treatment. ,vol. 119, pp. 379- 390 ,(2010) , 10.1007/S10549-009-0575-Y
L. Zhao, P. K. Vogt, Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms Proceedings of the National Academy of Sciences of the United States of America. ,vol. 105, pp. 2652- 2657 ,(2008) , 10.1073/PNAS.0712169105
Mattia Barbareschi, Lucia Veronica Cuorvo, Salvatore Girlando, Emma Bragantini, Claudio Eccher, Elena Leonardi, Antonella Ferro, Alessia Caldara, Renza Triolo, Chiara Cantaloni, Nicola Decarli, Enzo Galligioni, Paolo Dalla Palma, PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy Virchows Archiv. ,vol. 461, pp. 129- 139 ,(2012) , 10.1007/S00428-012-1267-2
Todd W. Miller, Justin M. Balko, Carlos L. Arteaga, Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer Journal of Clinical Oncology. ,vol. 29, pp. 4452- 4461 ,(2011) , 10.1200/JCO.2010.34.4879
Hervé Bonnefoi, Martine Piccart, Jan Bogaerts, Louis Mauriac, Pierre Fumoleau, Etienne Brain, Thierry Petit, Philippe Rouanet, Jacek Jassem, Emmanuel Blot, Khalil Zaman, Tanja Cufer, Alain Lortholary, Elisabet Lidbrink, Sylvie André, Saskia Litière, Lissandra Dal Lago, Véronique Becette, David A Cameron, Jonas Bergh, Richard Iggo, TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial Lancet Oncology. ,vol. 12, pp. 527- 539 ,(2011) , 10.1016/S1470-2045(11)70094-8